Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Files Fifth Patent Lawsuit Against Cellectis

NEW YORK (GenomeWeb News) – Precision BioSciences has filed a fifth lawsuit against French company Cellectis alleging patent infringement.

The litigation filed in the US District Court for the Eastern District of North Carolina alleges infringement by Cellectis on US Patent No. 8,129,134, which pertains to Precision Bio's Directed Nuclease Editor genome engineering technology. Precision seeks monetary damages and a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing the alleged infringing engineered meganucleases in the US.

The lawsuit is the latest in a patent fight between the two firms. In the past month, Precision Bio, headquartered in Research Triangle Park, NC, has sued Cellectis claiming infringement of US Patent No. 8,124,369, as well as US Patent Nos. 8,119,381 and 8,119,361.

In the fall, it sued Cellectis alleging infringement of US Patent No. 8,021,867. Cellectis also is suing Precision Bio, saying the company infringes on its US Patent No. 7,897,372.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.